Compare Stocks: ENTX, OCS, ALT, and AVTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.02 +0.5%	$2.89	$2.56 ▼ $6.44	$582.44M	0.27	4.32 million shs	3.00 million shs
AVTE Aerovate Therapeutics	$19.15 -3.0%	$19.71	$89.95 ▼ $99.05	$555.06M	0.95	53,591 shs	651,162 shs
ENTX Entera Bio	$2.85 -3.8%	$1.72	$0.91 ▼ $4.20	$138.46M	1.37	1.19 million shs	709,283 shs
OCS Oculis	$11.99 +0.8%	$13.43	$10.52 ▼ $34.47	$692.62M	0.44	487,827 shs	207,798 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+5.63%	+1.35%	-5.06%	-1.96%	-16.90%
AVTE Aerovate Therapeutics	0.00%	-1.64%	-8.18%	-19.45%	+186.65%
ENTX Entera Bio	-1.00%	-24.49%	+78.31%	+155.17%	+51.79%
OCS Oculis	+5.13%	+7.89%	-15.79%	-57.15%	-32.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.02 +0.5%	$2.89	$2.56 ▼ $6.44	$582.44M	0.27	4.32 million shs	3.00 million shs
AVTE Aerovate Therapeutics	$19.15 -3.0%	$19.71	$89.95 ▼ $99.05	$555.06M	0.95	53,591 shs	651,162 shs
ENTX Entera Bio	$2.85 -3.8%	$1.72	$0.91 ▼ $4.20	$138.46M	1.37	1.19 million shs	709,283 shs
OCS Oculis	$11.99 +0.8%	$13.43	$10.52 ▼ $34.47	$692.62M	0.44	487,827 shs	207,798 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+5.63%	+1.35%	-5.06%	-1.96%	-16.90%
AVTE Aerovate Therapeutics	0.00%	-1.64%	-8.18%	-19.45%	+186.65%
ENTX Entera Bio	-1.00%	-24.49%	+78.31%	+155.17%	+51.79%
OCS Oculis	+5.13%	+7.89%	-15.79%	-57.15%	-32.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.70	Moderate Buy	$15.71	421.20% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
ENTX Entera Bio	2.00	Hold	$9.00	215.90% Upside
OCS Oculis	2.80	Moderate Buy	$38.33	219.71% Upside

Current Analyst Ratings Breakdown

Latest ENTX, OCS, ALT, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	ENTX Entera Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ALT Altimmune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/22/2026	ALT Altimmune	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/11/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/3/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$42.00 ➝ $23.00
6/2/2026	ALT Altimmune	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
6/1/2026	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$49.00 ➝ $38.00
6/1/2026	OCS Oculis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $40.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$40K	14,658.18	N/A	N/A	$1.99 per share	1.52
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
ENTX Entera Bio	$40K	3,510.68	N/A	N/A	$0.29 per share	9.82
OCS Oculis	N/A	N/A	N/A	N/A	$4.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.93	N/A	N/A	N/A	-214,860.98%	-42.57%	-35.57%	8/11/2026 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
ENTX Entera Bio	-$11.44M	-$0.27	N/A	N/A	N/A	N/A	-83.31%	-70.83%	8/14/2026 (Estimated)
OCS Oculis	-$119.44M	-$2.13	N/A	N/A	N/A	-8,460.67%	-56.78%	-45.62%	8/6/2026 (Estimated)

Latest ENTX, OCS, ALT, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ENTX Entera Bio	-$0.08	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	ALT Altimmune	-$0.15	N/A	N/A	N/A	$0.00 million	N/A
8/6/2026	Q2 2026	OCS Oculis	-$0.48	N/A	N/A	N/A	$0.23 million	N/A
5/13/2026	Q1 2026	ALT Altimmune	-$0.25	-$0.18	+$0.07	-$0.18	$0.00 million	N/A
5/8/2026	Q1 2026	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	$0.07	N/A	N/A
5/8/2026	Q1 2026	OCS Oculis	-$0.49	-$0.63	-$0.14	-$0.61	$0.25 million	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.12	29.56	29.56
AVTE Aerovate Therapeutics	N/A	8.78	8.78
ENTX Entera Bio	N/A	7.93	7.93
OCS Oculis	0.01	5.18	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AVTE Aerovate Therapeutics	N/A
ENTX Entera Bio	14.11%
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
AVTE Aerovate Therapeutics	24.90%
ENTX Entera Bio	10.57%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	194.47 million	191.36 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
ENTX Entera Bio	20	49.29 million	44.08 million	Optionable
OCS Oculis	2	57.98 million	N/A	Not Optionable

ENTX, OCS, ALT, and AVTE Headlines

Recent News About These Companies

Oculis Holding AG (NASDAQ:OCS) Receives $38.33 Consensus PT from Analysts

August 4 at 3:59 AM | americanbankingnews.com

Oculis (NASDAQ:OCS) Shares Gap Up - Time to Buy?

August 3 at 12:39 PM | marketbeat.com

Oculis Receives Positive FDA Feedback Supporting Development Pathway for Privosegtor in Acute Multiple Sclerosis Relapses

August 3 at 4:10 AM | quiverquant.comQ

Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses

August 3 at 4:10 AM | quiverquant.comQ

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

August 3 at 4:00 AM | globenewswire.com

Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts

July 30, 2026 | marketbeat.com

Oculis (OCS) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

OCS Group to buy Mitie for $4.17 billion

July 21, 2026 | reuters.com

Oculis (NASDAQ:OCS) Lowered to "Strong Sell" Rating by Wall Street Zen

July 12, 2026 | marketbeat.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

July 8, 2026 | globenewswire.com

Oculis to Present Late-Stage Pipeline Update at Piper Sandler Virtual Ophthalmology Conference

July 2, 2026 | quiverquant.comQ

Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat

July 2, 2026 | quiverquant.comQ

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

July 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 25, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 23, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 18, 2026 | prnewswire.com

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

June 17, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 16, 2026 | globenewswire.com

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

June 11, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 11, 2026 | prnewswire.com

Oculis Holding AG to Present Privosegtor Development at Clinical Trials at the Summit 2026

June 11, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENTX, OCS, ALT, and AVTE Company Descriptions

Altimmune NASDAQ:ALT

$3.02 +0.02 (+0.50%)

As of 03:38 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Aerovate Therapeutics NASDAQ:AVTE

$19.15 -0.60 (-3.04%)

As of 08/3/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Entera Bio NASDAQ:ENTX

$2.85 -0.11 (-3.75%)

As of 03:37 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Oculis NASDAQ:OCS

$11.99 +0.10 (+0.84%)

As of 03:37 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, OCS, ALT, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, OCS, ALT, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, OCS, ALT, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTX, OCS, ALT, and AVTE Company Descriptions

Altimmune NASDAQ:ALT

Aerovate Therapeutics NASDAQ:AVTE

Entera Bio NASDAQ:ENTX

Oculis NASDAQ:OCS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, OCS, ALT, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, OCS, ALT, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, OCS, ALT, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTX, OCS, ALT, and AVTE Company Descriptions

Altimmune NASDAQ:ALT

Aerovate Therapeutics NASDAQ:AVTE

Entera Bio NASDAQ:ENTX

Oculis NASDAQ:OCS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools